antisera to human immunoglobulins. Primary infection with VZV was associated with early production of IgM and IgG antibodies and rapid development of lymphocyte transformation to VZV antigen. Among eight subjects with varicella tested 1 to 4 days after onset, seven patients had IgG and six patients had IgM antibodies; all patients had both IgG and IgM antibodies within 7 days. An IgM response was documented by radioimmunoassay in 18 of 26 patients with herpes zoster. VZV antibodies could be assayed by radioimmunoassay in unfractionated serum with commercial goat antisera to human immunoglobulin and commercial VZV antigen. VZV-specific IgG binding was present in all sera from 42 subjects with a VZV antibody titer of -1:8 as determined by indirect immunofluorescence and cellular immunity to VZV as determined by lymphocyte transformation and who had had varicella at least 20 years before testing. The geometric mean titer was 1:6,309, and titers were 21:16,384 in 20 subjects. Antibody was present as determined by radioimmunoassay in 14 samples negative by complement fixation and in five samples negative by complement fixation and immune adherence hemagglutination. No specific binding was observed in 21 sera from subjects who were not immune to VZV as determined by indirect immunofluorescence or lymphocyte transformation despite the presence of herpes simplex or cytomegalovirus antibody indicated by complement fixation in 15 sera. High titers of VZV IgM antibody were detected in unfractionated sera despite the presence of high titers of VZV IgG antibody. The VZV radioimmunoassay provided a sensitive and practical method for measuring VZV IgG and IgM antibodies.
Primary infection with varicella-zoster virus (VZV) is common in early childhood. Varicella is usually mild in healthy children but lifethreatening dissemination of the virus can occur in children with congenital immunodeficiency disorders or malignant diseases (7) . A reliable method for determining susceptibility to varicella is important because the severity of the infection can be reduced by the prophylactic administration of zoster immune globulin to immunocompromised children (13) . The indirect immunofluorescence methods for VZV antibody are sensitive, but these techniques require laboratory facilities for handling varicella virus, and their reliabiity can be affected by the subjective interpretation involved (26, 27) . The standard serological methods, such as the complement fixation technique, have not been useful in detecting VZV antibody for prolonged periods after the primary infection (25) . None of these methods has been easily adaptable to detect VZV immunoglobulin M (IgM) antibody in unfractionated serum.
The reactivation of latent VZV results in herpes zoster, which is a frequent occurrence among patients with malignancy and organ transplant recipients (18, 19) . In addition to its clinical application, a very sensitive assay for VZV IgG and IgM antibodies might detect deficiencies in antibody production that contribute to the pathogenesis of severe primary varicella and to the reactivation of latent VZV virus in immunocompromised patients.
The solid-phase radioimmunoassay (RIA) has been a sensitive method for the detection of IgG antibody to herpesviruses, including VZV, herpes simplex, and cytomegalovirus (9, 10, 16) , and has also been used to measure IgM antibody to cytomegalovirus (16) Laboratories, Inc., Naperville, Ill.) were infected with VZV. When several foci of infected cells were visible in each well, but before the cytopathic effect was extensive, the slides were fixed in cold acetone for 5 to 10 min. The fixed slides were stored at -70°C. Beginning at 1:8, serial dilutions of the serum samples to be tested and known negative and positive sera were coded and added in triplicate to the slide wells. After incubation for 1 h at 37°C, the slides were washed three times with PBS, and fluorescein-conjugated guinea pig antihuman IgG (Microbiological Research Co., Bountiful, Utah) diluted 1:20 was added. After 1 h of incubation at 37°C, the slides were washed three times with PBS and examined under a fluorescence microscope. The titer was read as the highest dilution of serum which showed fluorescence of infected cells in at least two of the three wells.
VZV cell-mediated immunity was assessed by in vitro lymphocyte transformation to VZV antigen as described previously (1) . Ficoll-Hypaque-separated peripheral blood mononuclear cells in 30% heat-inactivated human serum were incubated with VZV antigen for 5 days. Lymphocyte transformation was detected by comparing tritiated thymidine incorporation in antigen-stimulated cultures (;3H-antigen) with control antigen cultures (;3H-control). The results were expressed as a stimulation index ;H-antigen/3H-control. A stimulation index of at least threefold to VZV antigen was seen in normal seropositive subjects (1).
RIA for varicella-zoster IgG and IgM antibodies. The RIA for VZV IgG antibody was a modification of the method described by Friedman et al. (10) . Commercial VZV antigen (Flow Laboratories) was diluted to 1:5 with PBS, pH 7.2, and antigens prepared in this laboratory were diluted to 1:8 to 1:10 for use in the assay. Three lots of the commercial antigen were used with equivalent results. VZV antigen (0.025 ml) or uninfected control antigen (0.025 ml) was added to each well of a polyvinyl "U" plate (Dynatech Co., Alexandria, Va.), and the plate was allowed to dry overnight at room temperature. After one washing with PBS, the wells were filled with PBS containing 20% fetal calf serum and incubated for 1 h at 37°C. The wells were then rinsed twice with PBS and allowed to dry. Each serum sample to be tested was added to two wells containing antigen and to two control wells. The sera were diluted in PBS containing 10% fetal calf serum and 0.05% Tween 20 (J. T. Baker Chemical Co., Phillipsburg, N.J.) using a microtiter plate dilutor (Cooke Co., Alexandria, Va.). The plates were incubated at 37°C for 1 h and washed three times with PBS containing 0.05% Tween 20 before '2'l-labeled antihuman globulin was added.
The specific binding of VZV IgG antibody was assessed using goat antihuman IgG, specific for the Fc fragment (Cappel Laboratories, Downingtown, Pa.) that had been labeled with '2'I by a modified chloramine T method (20) . '25I-labeled monospecific goat antihuman IgM antibody (Tago Co., Burlingame, Calif.) purified by affinity chromatography was used to detect IgM antibody bound to the VZV antigen- For use in the RIA, the iodinated globulin was diluted to contain 2 X 10" cpm/ml. After preparation of the plates as described, '251-labeled antihuman IgG or IgM (0.025 ml per well) was added to each well, and the plates were incubated for 1 h at 37°C. The plates were then rinsed five times with cold PBS containing 0.05% Tween 20 and allowed to dry. The wells were separated by passing a "hot wire" below the surface of the plate, transferred to counting vials, and counted for 1 min in a gamma scintillation counter (Beckman Instruments, Inc., Fullerton, Calif.). Controls used in each assay included known positive and negative sera and diluent alone. Specific antibody binding was considered to be present at each serum dilution for which the ratio of the mean counts per minute (cpm) of the two wells containing serum and VZV antigen to the mean cpm of the two wells containing serum and control antigen was -2.5. The maximum cpm seen after the incubation of positive sera with antigen ranged from 6,000 to 15,000 cpm per well; the maximum cpm after the incubation of antibody-positive serum with control antigen ranged from 200 to 1,000 cpm per well. The incubation of negative serum or diluent with VZV antigen or with control antigen also produced counts in this range.
Separation of IgG and IgM serum fractions. The methods used for the removal or separation of IgG and IgM antibody from the test sera included the adsorption of IgG by using staphylococcal protein A (3), the separation of IgG and IgM by using a gel filtration technique, and incubation with 2-mercaptoethanol (2). The gel purification procedure, kindly performed by Gregory Filice, used Bio-Gel A-5M, which is a 6% agarose gel (Bio-Rad Laboratories, Richmond, Calif.) to separate 7S and 19S globulin.
Rheumatoid factor. Sera that were positive in the VZV IgM assay were tested for rheumatoid factor with a commercial latex agglutination method (Calbiochem, La Jolla, Calif.) (21) . VZV IgG and IgM antibody titers were assayed in sera from six adults with high titers of rheumatoid factor, ranging from 1:1,280 to 1:5,120, who had had varicella at least 20 With the commercial antigen, specific IgG binding was detected in all 42 sera from subjects remote from infection who had VZV antibody as determined by IFA (Fig. 1) . No specific binding was observed in 21 sera from subjects who were not immune to varicella by IFA or in vitro lymphocyte transformation (Fig. 1) . When 25I-labeled goat antihuman IgM was used to detect bound IgM, ail 8 patients with acute varicella and 18 of 26 patients with acute herpes zoster had VZV IgM antibody ( Fig. 1 and 2) . None of the 15 subjects remote from infection who had VZV IgG antibody had detectable VZV IgM antibody (Fig. 1) . No specific binding occurred when sera from nine subjects who were not immune to varicella were tested. Binding curves for '251-labeled antihuman IgG and IgM in unfractionated serum from a subject with acute varicella are shown in Fig. 3 .
Twelve serum samples from seropositive subjects were tested to determine the reproducibility of the assay. Of the 12 sera, 10 had IgG titers within a twofold dilution, and two samples showed a greater than fourfold variation in titer.
As is the case with other methods, it was necessary to test paired sera in the same assay to obtain the most accurate comparison of VZV IgG and IgM antibody titers early and later in the course of acute infection (Fig. 2) .
Some assays for the detection of viral antibody by solid-phase RIA have been based on a comparison of the '25I-labeled antihuman IgG bound after incubating the test serum with viral antigen and the binding measured when a known negative serum was incubated with the antigen (15) . Specific VZV IgG binding could be assessed with reference to a standard negative serum without significantly altering the antibody titer in 20 seropositive subjects. However, the elimination of the incubation of each serum with control antigen produced false-positive results among subjects who had negative VZV IFA titers and no lymphocyte transformation to VZV antigen. Of 10 nonimmune subjects, 2 showed binding ratios greater than 2.5 at serum dilutions of 1:16 when binding was assessed in relation to a standard negative serum. The binding ratios were consistently less than 2.5 when the calculation was based on binding of the subject's serum to control antigen.
The sensitivity of the VZV RIA for measuring IgG antibody was evaluated in 14 subjects who had no antibody to varicella as determined by complement fixation (Fig. 4) (Fig. 4) .
Cross-reactivity with herpes simplex virus and cytomegalovirus antibodies did not appear to affect the VZV antibody results by RIA. Despite the presence of antibody to herpes simplex virus in six subjects and antibody to cytomegalovirus in nine subjects, VZV RIA titers were negative in those individuals who were VZV-susceptible as determined by IFA and lymphocyte transformation. When the assay was used to measure VZV IgG antibody in immune subjects with no recent VZV infection, the VZV GMTs were equivalent between groups that had antibody to herpes simplex virus or cytomegalovirus and those that did not. The VZV GMT in 17 herpes simplex virus-seropositive subjects was 1:2,454 compared with 1:5,623 in 18 herpes simplex virus-seronegative subjects; the VZV GMTs in 15 cytomegalovirus-seropositive and 17 cytomegalovirus-seronegative subjects were 1:3,238 and 1: 5,254, respectively.
Sera from six immune subjects without recent VZV infection who had VZV IgG antibody titers ranging from 1:1,024 to 1:2.6 x 105 and who also had high titers of rheumatoid factor were evaluated to determine whether rheumatoid factor produced a false-positive result in the VZV IgM assay. Rheumatoid factor, which is usually an IgM antibody against IgG, could attach to the VZV IgG bound to the VZV antigen. (Fig. 1 and 2 ). The IgM antibody detected in the patients with acute infection was considered VZV specific because none of the sera from these patients contained rheumatoid factor. Both IgG and IgM antibodies to VZV were present very early in the course of primary varicella infection in normal subjects (Fig. 2 ). Among eight patients tested within 4 days after the onset of exanthem, seven had IgG antibody and six had IgM antibody. VZV IgG and IgM antibody titers continued to increase 7 to 16 days after the appearance of the rash in most patients. The production of VZV IgG and IgM antibody within a few days after the onset of clinical varicella was accompanied by a positive in vitro lymphocyte transformation response to VZV antigen in four patients. Antibody production preceded lymphocyte transformation in the other four patients. The only patient with no detectable VZV IgG, IgM, or lymphocyte transformation was tested just 12 h after appearance of the exanthem.
VZV IgM antibody was detectable by RIA in 18 of 26 patients with herpes zoster, including 13 patients tested 3 to 5 weeks after the onset of the infection (Fig. 1) the total IgG had been reduced to less than 0.9 to 1.8 mg/ml. IgM antibody was not detected after the treatment of VZV IgM-positive sera with 2-mercaptoethanol, but IgG antibody persisted (Fig. 3) . (11) . The VZV IgM titers we obtained in serum from subjects with herpes zoster were as high as those in patients with primary varicella in some cases. The presence of VZV IgM antibody does not differentiate primary varicella from generalized herpes zoster.
DISCUSSION
The studies of kinetics of the immune response to primary varicella showed that both IgM and IgG antibody and VZV-specific lymphocyte transformation develop very early in the course of clinical infection in otherwise healthy subjects. The simultaneous appearances of IgG and IgM antibodies within 4 days after the onset of varicella demonstrated by RIA contrast with the apparent delay in VZV IgM production assessed by the IFA method (5). Cradock-Watson et al. detected IgM antibody within 7 days in 31% of patients, when 100% of patients had high titers of IgM antibody by RIA within 7 days. In addition to comparing the antibody response to varicella and herpes zoster in normal subjects with the response in immunocompromised patients, the VZV RIA for IgG and IgM antibody will be useful to determine whether the antibody response to the varicella vaccine now being evaluated in high-risk patients is similar to that seen after natural infection (14) . The sensitivity of the method will allow further investigation of the role of maternally acquired antibody in modifying varicella, the effect of reexposure of immune subjects to the virus, and other aspects of the natural history of VZV infection.
